JP2018501813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501813A5 JP2018501813A5 JP2017543310A JP2017543310A JP2018501813A5 JP 2018501813 A5 JP2018501813 A5 JP 2018501813A5 JP 2017543310 A JP2017543310 A JP 2017543310A JP 2017543310 A JP2017543310 A JP 2017543310A JP 2018501813 A5 JP2018501813 A5 JP 2018501813A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- amino acid
- binding fragment
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 106
- 239000000427 antigen Substances 0.000 claims description 84
- 108091007433 antigens Proteins 0.000 claims description 84
- 102000036639 antigens Human genes 0.000 claims description 84
- 239000012634 fragment Substances 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 38
- 210000000225 synapse Anatomy 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 21
- 238000006467 substitution reaction Methods 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 18
- 230000024203 complement activation Effects 0.000 claims description 18
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 206010047115 Vasculitis Diseases 0.000 claims description 12
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 12
- 206010018910 Haemolysis Diseases 0.000 claims description 10
- 230000008588 hemolysis Effects 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 208000017442 Retinal disease Diseases 0.000 claims description 9
- 206010038923 Retinopathy Diseases 0.000 claims description 9
- 239000012472 biological sample Substances 0.000 claims description 8
- 108010047295 complement receptors Proteins 0.000 claims description 8
- 102000006834 complement receptors Human genes 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 6
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 6
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 4
- 102100032752 C-reactive protein Human genes 0.000 claims description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 206010057249 Phagocytosis Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 230000008782 phagocytosis Effects 0.000 claims description 4
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 102000009109 Fc receptors Human genes 0.000 claims description 3
- 108010087819 Fc receptors Proteins 0.000 claims description 3
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 201000002563 Histoplasmosis Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 3
- 206010035669 Pneumonia aspiration Diseases 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 3
- 201000001949 Retinal Vasculitis Diseases 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 201000001326 acute closed-angle glaucoma Diseases 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 238000011316 allogeneic transplantation Methods 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 3
- 201000009807 aspiration pneumonia Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 201000000159 corneal neovascularization Diseases 0.000 claims description 3
- 208000001309 degenerative myopia Diseases 0.000 claims description 3
- 230000004340 degenerative myopia Effects 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 201000011190 diabetic macular edema Diseases 0.000 claims description 3
- 230000009429 distress Effects 0.000 claims description 3
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 3
- 206010014801 endophthalmitis Diseases 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 206010043207 temporal arteritis Diseases 0.000 claims description 3
- 208000037816 tissue injury Diseases 0.000 claims description 3
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 208000000104 Arthus reaction Diseases 0.000 claims description 2
- 102000004082 Calreticulin Human genes 0.000 claims description 2
- 108090000549 Calreticulin Proteins 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 108010062119 complement 1q receptor Proteins 0.000 claims description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 2
- 230000016396 cytokine production Effects 0.000 claims description 2
- 230000004041 dendritic cell maturation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000016784 immunoglobulin production Effects 0.000 claims description 2
- 230000006724 microglial activation Effects 0.000 claims description 2
- 210000001640 nerve ending Anatomy 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 206010020974 Hypocomplementaemia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008753 endothelial function Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000007470 synaptic degeneration Effects 0.000 description 4
- 230000000946 synaptic effect Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 102000004584 Somatomedin Receptors Human genes 0.000 description 2
- 108010017622 Somatomedin Receptors Proteins 0.000 description 2
- 102000007238 Transferrin Receptors Human genes 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000013138 pruning Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- -1 TMEM30 (A) Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- GBVKRUOMSUTVPW-AHNVSIPUSA-N chembl1089636 Chemical compound N([C@H]([C@@H](OC(=O)CCC(=O)N[C@@H](C(O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 GBVKRUOMSUTVPW-AHNVSIPUSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011893 micropositron emission tomography Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 108010046239 paclitaxel-Angiopep-2 conjugate Proteins 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021155093A JP7275223B2 (ja) | 2014-11-05 | 2021-09-24 | ヒト化抗補体因子Ｃ１ｑ抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075793P | 2014-11-05 | 2014-11-05 | |
| US62/075,793 | 2014-11-05 | ||
| PCT/US2015/059185 WO2016073685A1 (en) | 2014-11-05 | 2015-11-05 | Humanized anti-complement factor c1q antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021155093A Division JP7275223B2 (ja) | 2014-11-05 | 2021-09-24 | ヒト化抗補体因子Ｃ１ｑ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501813A JP2018501813A (ja) | 2018-01-25 |
| JP2018501813A5 true JP2018501813A5 (https=) | 2018-12-13 |
| JP6951246B2 JP6951246B2 (ja) | 2021-10-20 |
Family
ID=55909791
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543310A Active JP6951246B2 (ja) | 2014-11-05 | 2015-11-05 | ヒト化抗補体因子Ｃ１ｑ抗体及びその使用 |
| JP2021155093A Active JP7275223B2 (ja) | 2014-11-05 | 2021-09-24 | ヒト化抗補体因子Ｃ１ｑ抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021155093A Active JP7275223B2 (ja) | 2014-11-05 | 2021-09-24 | ヒト化抗補体因子Ｃ１ｑ抗体及びその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10316081B2 (https=) |
| EP (2) | EP3215527B1 (https=) |
| JP (2) | JP6951246B2 (https=) |
| KR (1) | KR102626877B1 (https=) |
| CN (1) | CN107207587B (https=) |
| AU (1) | AU2015343029B2 (https=) |
| BR (1) | BR112017009297B1 (https=) |
| DK (1) | DK3215527T3 (https=) |
| ES (1) | ES3013108T3 (https=) |
| FI (1) | FI3215527T3 (https=) |
| HR (1) | HRP20250246T1 (https=) |
| HU (1) | HUE070383T2 (https=) |
| IL (1) | IL252026B (https=) |
| LT (1) | LT3215527T (https=) |
| PL (1) | PL3215527T3 (https=) |
| PT (1) | PT3215527T (https=) |
| RS (1) | RS66604B1 (https=) |
| SG (2) | SG11201703667SA (https=) |
| SI (1) | SI3215527T1 (https=) |
| SM (1) | SMT202500118T1 (https=) |
| WO (1) | WO2016073685A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2996722A4 (en) * | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| WO2015006507A1 (en) | 2013-07-09 | 2015-01-15 | Annexon, Inc. | Methods of treatment for alzheimer's disease and huntington's disease |
| WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| KR20190005944A (ko) * | 2016-05-09 | 2019-01-16 | 애넥슨, 인코포레이티드 | 척수성 근위축 치료용 조성물 및 방법 |
| CA3030872A1 (en) * | 2016-07-19 | 2018-01-25 | Annexon, Inc. | Compositions and methods for treating frontotemporal dementia |
| US20190248885A1 (en) * | 2016-10-26 | 2019-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Neuronal and Oligodendrocyte Survival Modulation |
| CN111566214B (zh) * | 2017-07-06 | 2024-03-08 | 日东纺绩株式会社 | 抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂 |
| EP3710589A4 (en) * | 2017-11-14 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C1S ANTIBODIES AND METHOD OF USING |
| CR20200542A (es) * | 2018-04-13 | 2021-01-18 | Chugaiseiyaku Kk | Anticuerpos anti-componente de complemento y métodos de uso |
| CA3118453A1 (en) * | 2018-11-02 | 2020-05-07 | The Regents Of The University Of California | Compositions and methods for treating brain injury |
| WO2020103100A1 (en) * | 2018-11-22 | 2020-05-28 | Suzhou Kanova Biopharmaceutical Co., Ltd. | An anti-b7-h3 antibody |
| WO2020121282A1 (en) | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| MX2021013441A (es) | 2019-05-15 | 2021-12-10 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigenos, composicion farmaceutica y metodo. |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| WO2021076991A1 (en) * | 2019-10-17 | 2021-04-22 | Annexon, Inc. | Compositions and methods for treating blood disorders |
| US20240034775A1 (en) * | 2020-05-05 | 2024-02-01 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Compositions and methods for treating epilepsy |
| CA3195798A1 (en) * | 2020-10-16 | 2022-04-21 | Ted Yednock | Compositions and methods for treating blood disorders |
| CN117241828A (zh) | 2021-03-31 | 2023-12-15 | 美国比奥维拉迪维股份有限公司 | 减少冷凝集素病患者的手术相关溶血 |
| AU2022293581A1 (en) * | 2021-06-18 | 2024-01-25 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
| GB202113673D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| GB202113674D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| WO2023114763A1 (en) * | 2021-12-13 | 2023-06-22 | Annexon, Inc. | Anti-complement factor c1q antibodies with single binding arms and uses thereof |
| WO2023126821A1 (en) * | 2021-12-29 | 2023-07-06 | Curateq Biologics Private Limited | C1q binding assay |
| CN117085132A (zh) * | 2022-05-20 | 2023-11-21 | 浙江大学 | 阻断胸膜间皮细胞cd93的活性物质及应用 |
| CN119371528B (zh) * | 2024-10-30 | 2025-06-24 | 泰州市人民医院 | 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用 |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545A (en) | 1848-05-02 | Improvement in machinery for separating gold | ||
| US16567A (en) | 1857-02-03 | Amos jacobs | ||
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4595654A (en) | 1983-11-07 | 1986-06-17 | Immunomedics Inc. | Method for detecting immune complexes in serum |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69334095T2 (de) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2168349A1 (en) | 1993-07-30 | 1995-02-09 | Lingxun Duan | Intracellular immunization |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US20020058311A1 (en) * | 1995-06-13 | 2002-05-16 | Browne Michael Jospeh | Chimeric leptin fused to immunoglobulin domain and use |
| WO1998023761A1 (en) | 1996-11-27 | 1998-06-04 | Genentech, Inc. | HUMANIZED ANTI-CD11a ANTIBODIES |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999010492A1 (en) | 1997-08-26 | 1999-03-04 | Zymogenetics, Inc. | Adipocyte-specific protein homologs |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030170781A1 (en) | 1999-07-01 | 2003-09-11 | Zymogenetics, Inc. | Secreted protein zacrp4 |
| CN100427603C (zh) | 1999-10-04 | 2008-10-22 | 麦迪卡格公司 | 调控外源基因转录的方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| WO2002005634A2 (en) | 2000-07-13 | 2002-01-24 | University Of South Florida | Transgenic animal and methods |
| AU2002226074A1 (en) | 2000-10-26 | 2002-05-06 | Wisconsin Alumni Research Foundation. | E. coli 0157:h7 c1 esterase inhibitor-binding protein stce and uses thereof |
| US7189830B2 (en) * | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
| CA2478313A1 (en) | 2001-11-07 | 2003-06-26 | Human Genome Sciences, Inc. | 41 human secreted proteins |
| US20040248156A1 (en) | 2001-12-03 | 2004-12-09 | Tianhua Hu | Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides |
| US20050214786A1 (en) | 2002-02-22 | 2005-09-29 | Human Genome Sciences, Inc. | 26 human secreted proteins |
| US20040119010A1 (en) | 2002-11-01 | 2004-06-24 | The Regents Of The University Of Colorado | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| US8329169B2 (en) | 2003-05-15 | 2012-12-11 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
| US20050019326A1 (en) * | 2003-06-16 | 2005-01-27 | The Brigham And Women's Hospital, Inc. | C1q complement inhibitors and methods of use thereof |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US7544855B2 (en) | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
| WO2006063150A2 (en) | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| TWI319708B (en) | 2005-10-14 | 2010-01-21 | Methods and compositions for altering cell fuction | |
| US9480658B2 (en) * | 2005-12-09 | 2016-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| US8148330B2 (en) | 2005-12-09 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| CA2662480C (en) | 2006-09-05 | 2016-11-08 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| CN101657097A (zh) * | 2007-03-01 | 2010-02-24 | 先进视觉疗法公司 | 以炎症为特征的疾病的治疗 |
| UY31520A1 (es) * | 2007-12-11 | 2009-08-03 | Proteinas de union a antigenos | |
| WO2010065425A1 (en) * | 2008-12-01 | 2010-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detection of complement fixing antibodies |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| WO2012176765A1 (ja) | 2011-06-24 | 2012-12-27 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ－カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| LT2794905T (lt) * | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| CN102636654A (zh) * | 2012-04-28 | 2012-08-15 | 上海北加生化试剂有限公司 | 检测人血清中补体Clq浓度的试剂盒及其方法 |
| KR102339315B1 (ko) | 2012-06-18 | 2021-12-15 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2014161570A1 (en) * | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| EP2983710B1 (en) * | 2013-04-09 | 2019-07-31 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| EP2996722A4 (en) * | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| WO2015006507A1 (en) * | 2013-07-09 | 2015-01-15 | Annexon, Inc. | Methods of treatment for alzheimer's disease and huntington's disease |
| KR102264548B1 (ko) | 2014-11-21 | 2021-06-16 | 삼성전자주식회사 | 반도체 패키지 및 그 제조 방법 |
| WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
-
2015
- 2015-11-05 HU HUE15857258A patent/HUE070383T2/hu unknown
- 2015-11-05 SM SM20250118T patent/SMT202500118T1/it unknown
- 2015-11-05 EP EP15857258.6A patent/EP3215527B1/en active Active
- 2015-11-05 SG SG11201703667SA patent/SG11201703667SA/en unknown
- 2015-11-05 KR KR1020177015260A patent/KR102626877B1/ko active Active
- 2015-11-05 BR BR112017009297-2A patent/BR112017009297B1/pt active IP Right Grant
- 2015-11-05 JP JP2017543310A patent/JP6951246B2/ja active Active
- 2015-11-05 PL PL15857258.6T patent/PL3215527T3/pl unknown
- 2015-11-05 CN CN201580072390.6A patent/CN107207587B/zh active Active
- 2015-11-05 LT LTEPPCT/US2015/059185T patent/LT3215527T/lt unknown
- 2015-11-05 SG SG10202008810QA patent/SG10202008810QA/en unknown
- 2015-11-05 RS RS20250249A patent/RS66604B1/sr unknown
- 2015-11-05 US US14/933,517 patent/US10316081B2/en active Active
- 2015-11-05 WO PCT/US2015/059185 patent/WO2016073685A1/en not_active Ceased
- 2015-11-05 FI FIEP15857258.6T patent/FI3215527T3/fi active
- 2015-11-05 AU AU2015343029A patent/AU2015343029B2/en active Active
- 2015-11-05 HR HRP20250246TT patent/HRP20250246T1/hr unknown
- 2015-11-05 ES ES15857258T patent/ES3013108T3/es active Active
- 2015-11-05 DK DK15857258.6T patent/DK3215527T3/da active
- 2015-11-05 PT PT158572586T patent/PT3215527T/pt unknown
- 2015-11-05 SI SI201532057T patent/SI3215527T1/sl unknown
- 2015-11-05 EP EP23197405.6A patent/EP4295911A3/en active Pending
-
2017
- 2017-04-30 IL IL252026A patent/IL252026B/en unknown
-
2019
- 2019-05-17 US US16/415,278 patent/US20190315845A1/en not_active Abandoned
-
2020
- 2020-04-08 US US16/843,449 patent/US20210115119A1/en not_active Abandoned
-
2021
- 2021-09-24 JP JP2021155093A patent/JP7275223B2/ja active Active
-
2023
- 2023-01-24 US US18/100,885 patent/US20240025974A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501813A5 (https=) | ||
| JP2016526393A5 (https=) | ||
| CN110799531B (zh) | 抗PHF-tau抗体及其用途 | |
| TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| JP2019501132A5 (https=) | ||
| US11472882B2 (en) | Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| CN108779171B (zh) | 抗补体因子c1q的fab片段及其应用 | |
| US9856321B2 (en) | Anti-DR5 antibodies, polynucleotides and methods | |
| TWI866304B (zh) | 抗EphA4抗體 | |
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| Hettmann et al. | Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation | |
| WO2022237647A1 (zh) | 针对dll3的结合分子及其应用 | |
| CN112243443A (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
| WO2023212719A1 (en) | Compositions and methods for treating ocular diseases | |
| WO2024077246A1 (en) | Formulations for anti-c1q antibodies | |
| JPWO2022087339A5 (https=) | ||
| CN120035606A (zh) | 一种治疗实体瘤的方法 | |
| HK40036076A (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| NZ732156B2 (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| NZ732156A (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| NZ769628B2 (en) | Humanized anti-complement factor C1q antibodies and uses thereof |